Theralase Releases Q222 Interim Financial Statements

Rhea-AI Summary

Theralase Technologies Inc. (TSXV: TLT, OTCQB: TLTFF) has released its unaudited 2Q2022 financial results, showing a 28% increase in total revenue year-over-year, totaling CAD 552,442. The gross margin rose to 51%, up from 46% in 2021. Operating expenses surged by 43% to CAD 3,227,954, primarily due to higher research and development costs, which rose 68%. The net loss for the period was CAD 2,947,168, exacerbated by increased spending in its ACT division. Operational highlights include updates on patient enrollment and ongoing clinical studies.

Positive

• 28% increase in total revenue to CAD 552,442.
• Gross margin improved to 51% from 46% year-over-year.
• Decreased selling expenses by 15% and administrative expenses by 9%.
• Successful launch of 12 clinical study sites for Study II.

Negative

• Net loss increased by 43% to CAD 2,947,168.
• Operating expenses rose by 43%, primarily due to increased R&D spending.
• Delays in patient enrollment for Study II attributed to COVID-19.

TORONTO, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Theralase^® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated PhotoDynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers has released the Company’s unaudited 2Q2022 condensed interim consolidated Financial Statements (“Financial Statements”).

Financial Highlights:

For the six-month period ended June 30th:

Audited Consolidated Statements of Operations In Canadian Dollars	2022		2021		% Change
Revenue
Canada	426,990		384,154		11	%
United States	125,452		32,656		284	%
International	0		13,189		-100	%
Total Revenue	552,442		429,999		28	%
Cost of Sales	271,656		230,370		18	%
Gross Margin	280,786		199,629		41	%
Gross Margin as a percentage of sales	51	%	46	%
Operating Expenses
Selling Expenses	167,139		197,400		-15	%
Administrative Expenses	734,081		802,271		-8	%
Research and Development Expenses – CLT Division	105,353		88,141		20	%
Research and Development Expenses – ACT Division	2,233,502		1,305,437		71	%
Other(1)	(12,120	)	(131,344	)	-91	%
Total Operating Expenses	3,227,954		2,261,905		43	%
Net Loss	(2,947,168	)	(2,062,276	)	43	%

(1) Other represents gain from legal settlement, (gain) loss on foreign exchange, interest accretion on lease liabilities and interest income

Total revenue increased 28%, year over year, and is primarily attributed to the anticipated Canadian and US economic recovery from the COVID-19 pandemic in 2020 and 2021.

Cost of sales for the six-month period ended June 30, 2022 was $271,656 or 49% of revenue resulting in a gross margin of $280,786 or 51% of revenue. In comparison, the cost of sales in 2021 was $230,370 or 54% of revenue resulting in a gross margin of $199,629 or 46% of revenue. The gross margin increase, as a percentage of sales, year over year, is primarily attributed to a decrease in labour and material costs.

Selling expenses for the six-month period ended June 30, 2022, decreased to $167,139, from $197,400 in 2021, a 15% decrease. The decrease in selling expenses is primarily attributed to the COVID-19 pandemic, resulting in reduced advertising (52%), and salaries (15%).

Administrative expenses for the six-month period ended June 30, 2022, decreased to $734,0 from $802,271 in 2021, a 9% decrease. The decrease in administrative expenses is primarily attributed to decreased spending in professional fees (5%) and insurance expenses (17%). Stock based compensation expense decreased 60% in 2022 due to a reduction in stock options granted.

Net research and development expenses for the six-month period ended June 30, 2022, increased to $2,338,855 from $1,393,578 in 2021, a 68% increase. The increase in research and development expenses is primarily attributed to the costs related to Study II. Research and development expenses represented 72% of the Company’s operating expenses and represents investment into the research and development of the Company’s ACT technology.

The net loss for the six-month period ended June 30, 2022 was $2,947,168, which included $254,616 of net non-cash expenses (i.e.: amortization, stock-based compensation expense and foreign exchange gain/loss). This compared to a net loss in 2021 of $2,062,276, which included $365,690 of net non-cash expenses. The ACT division represented $2,552,720 of this loss (87%) for the six-month period ended June 30, 2022.

The increase in net loss is primarily attributed to increased spending in research and development expenses in Study II.

Operational Highlights:

1. Break Through Designation Update. In 2020, the FDA granted Theralase^® Fast Track Designation (“FTD”) for Study II. As a Fast Track designee, Theralase^® has access to early and frequent communications with the FDA to discuss Theralase^®’s development plans and ensure the timely collection of clinical data to support the approval process. FTD can also lead to Break Through Designation (“BTD”), Accelerated Approval (“AA”) and/or Priority Review, if certain criteria are met, which the FDA has previously defined to the Company for BTD to represent a complete clinical dataset on approximately 20 to 25 patients enrolled, treated and assessed, who demonstrate significant safety and efficacy clinical outcomes.

In 2021, Theralase^® completed its first significant milestone of Study II by enrolling and treating 25 patients. The Company will compile a clinical data report for submission to the FDA in support of the grant of a BTD approval after completion of the 450 day assessment for 25 patients, expected in 4Q2022, subject to the Clinical Study Sites (“CSSs”) availability to complete all required assessments.

2. COVID-19 Pandemic Update. In the ACT division, the Company continues to experience delays in patient enrollment and treatment rates in Study II due to the ongoing COVID-19 pandemic; however, these rates have improved as Canada and the US commence their recovery from the business and economic impacts of the COVID-19 pandemic.

In the CLT division, the Company continues to experience variations in sales and the timing of these sales due to the ongoing COVID-19 pandemic and has taken actions to minimize expenses by eliminating non-essential personnel and imposing a temporary hiring freeze, commencing in March 2020. The Company lifted the temporary hiring freeze in 4Q2021, now that the Canadian and United States economies have started to demonstrate a sustainable business and economic recovery from COVID-19.

3. Clinical study site status and update. The Company has successfully launched five CSSs in Canada and seven CSSs in the US that are open for patient enrollment and treatment for a total of 12 CSSs.

To date, Study II has provided the primary study treatment for 42 patients; including, three patients from the Phase Ib NMIBC Clinical Study treated at the Therapeutic Dose for a total of 45 patients.

An analysis of Evaluable Patients (defined as patients who have been evaluated by the principal investigator and thus excludes data pending), in Study II provides the following interim analysis (including three patients from the Phase Ib NMIBC Clinical Study treated at the Therapeutic Dose):

Assessment	90 Day	180 Day	270 Day	360 Day	450 Day
Complete Response (“CR”)	50%	47%	41%	35%	21%
Partial Response (“PR”)	16%	26%	22%	12%	13%
Total Response (“CR + PR”)	66%	74%	63%	46%	33%
Evaluable Patients	38	34	32	26	24

The clinical data to date demonstrates a strong initial CR (50%) and a strong duration of that response for 450 days (21%).

For a more comprehensive analysis of the interim data please refer to Management’s Discussion and Analysis (“MD&A”) for the six-month period ended June 30, 2022.

Dr. Vera Madzarevic, Ph.D. has left the employ of the Company and Dr Arkady Mandel, M.D., Ph.D., D.Sc., will continue in his role as lead for the Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study as the Interim Chief Executive Officer and Chief Scientific Officer.

4. Additional cancer indications. The Company has demonstrated significant anti-cancer efficacy of Rutherrin^®, when activated by laser light or radiation treatment across numerous preclinical models; including: Glio Blastoma Multiforme (“GBM”) and Non-Small Cell Lung Cancer (“NSCLC”). The Company has commenced Non - Good Laboratory Practices (“GLP”) toxicology studies with Rutherrin^® in animals to help determine the maximum recommended human dose of the drug, when administered systemically into the human body, via intravenous injections. Theralase plans to commence GLP toxicology studies in animals in 4Q2022.

5. COVID-19 Research Update. In April 2021, Theralase^® executed a Collaborative Research Agreement (“CRA”) with the National Microbiology Laboratory, Public Health Agency of Canada (“PHAC”) for the research and development of a Canadian-based SARS-CoV-2 (“COVID-19”) vaccine. Under the terms of the agreement, Theralase^® and PHAC are collaborating on the development and optimization of a COVID-19 vaccine by treating the SARS-CoV-2 virus grown on cell lines with Theralase^®’s patented PDC and then light activating it with Theralase^®’s proprietary TLC-3000A light technology to inactivate the virus and create the fundamental building blocks of a COVID-19 vaccine. This wholly inactivated virus would then be purified and used to inoculate naive animals followed by challenge with the SARS-CoV-2 virus, to ascertain the efficacy of the vaccine. The project is entitled, “Photo Dynamic Compound Inactivation of SARS-CoV-2 Vaccine” and commenced in mid-April 2021.

In February, 2022 Theralase^® reported that PHAC had demonstrated that light-activated TLD-1433, was effective in rapidly inactivating the SARS-CoV-2 virus by up to 99.99%, compared to control in an in vitro study. Further research is required to confirm these findings.

These results have now laid the groundwork for the next phase of the CRA, which is evaluating the Theralase^® COVID-19 vaccine in the ability to prevent animals from contracting COVID-19, when exposed to the virus, which is expected to commence and be completed in 4Q2022.

Note: The Company does not claim or profess that they have the ability to treat, cure or prevent the contraction of the COVID-19 coronavirus.

About Study II
Study II utilizes the therapeutic dose of TLD-1433 (0.70 mg/cm²) activated by the proprietary TLC-3200 medical laser system. Study II is focused on enrolling and treating approximately 100 to 125 BCG-Unresponsive NMIBC Carcinoma In-Situ (“CIS”) patients in up to 15 Clinical Study Sites (“CSS”) located in Canada and the United States.

About TLD-1433
TLD-1433 is a patented PDC with over 10 years of published peer reviewed preclinical research and is currently under investigation in Study II.

About Theralase^® Technologies Inc.
Theralase^® is a clinical stage pharmaceutical company dedicated to the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.
Additional information is available at www.theralase.com and www.sedar.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements
This news release contains "forward-looking statements" within the meaning of applicable Canadian securities laws. Such statements include, but are not limited to, statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds and their drug formulations and a COVID-19 vaccine. Forward looking statements may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions including statements related to the current expectations of Company's management for future research, development and commercialization of the Company’s Photo Dynamic Compounds and their drug formulations, including preclinical research, clinical studies and regulatory approvals.

These statements involve significant risks, uncertainties and assumptions; including, the ability of the Company to: adequately fund, and secure the requisite regulatory approvals to successfully complete a Phase II NMIBC clinical study in a timely fashion and implement its development plans. Other risks include: the ability of the Company to successfully commercialize its drug formulations, the risk that access to sufficient capital to fund the Company’s operations may not be available or may not be available on terms that are commercially favorable to the Company, the risk that the Company’s drug formulations may not be effective against the diseases tested in its clinical studies, the risk that the Company’s fails to comply with the term of license agreements with third parties and as a result loses the right to use key intellectual property in its business, the Company’s ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises, such as COVID-19. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.

Readers should not unduly rely on these forward- looking statements which are not a guarantee of future performance. There can be no assurance that forward looking statements will prove to be accurate as such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements.

Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements.

For More Information:
1.866.THE.LASE (843-5273)
416.699.LASE (5273)
www.theralase.com

Kristina Hachey CPA, Chief Financial Officer
khachey@theralase.com
www.theralase.com

 

FAQ

What were Theralase's total revenues for 2Q2022?

Theralase reported total revenues of CAD 552,442 for the six-month period ended June 30, 2022.

How did Theralase's gross margin change in 2Q2022?

The gross margin increased to 51% in 2Q2022, up from 46% in 2021.

What was Theralase's net loss for the first half of 2022?

The net loss for Theralase was CAD 2,947,168 for the six-month period ended June 30, 2022.

How much did Theralase's research and development expenses increase?

Research and development expenses rose by 68% to CAD 2,338,855 in 2Q2022.

What operational updates were provided in Theralase's 2Q2022 report?

Theralase successfully launched 12 clinical study sites for patient enrollment in Study II.